Literature DB >> 3535251

Anti-HTLV III ELISA and Western blot testing in a blood donor population: implications for donor notification.

S Kleinman, H Anton-Guirigis, B D Culver, T H Taylor, H E Prince, H S Kaplan.   

Abstract

We have evaluated the western blot (WB) test for distinguishing anti-HTLV III ELISA-positive donors who have likely been exposed to HTLV III from those that are false positives. Of 1,955 donors, 26 were positive for anti-HTLV III by ELISA testing. Only 6 (23%) were positive by WB: 5 of these 6 were male homosexuals with multiple partners and 5 of 6 had low Th/Ts ratios. The WB-positive donors gave the highest absorbance values in the anti-HTLV III ELISA assay. The immunologic abnormalities in the WB-positive donors suggest that they should be notified of their test results. We conclude that basing a donor notification policy on WB results is the optimum public health strategy for blood banks at the present time.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3535251     DOI: 10.1111/j.1423-0410.1986.tb00231.x

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  3 in total

1.  Preferential loss of Leu 8-, CD45R, HLA-DR+ CD8 cell subsets during in vitro culture of mononuclear cells from human immunodeficiency virus type I (HIV)-seropositive former blood donors.

Authors:  H E Prince; C D Czaplicki
Journal:  J Clin Immunol       Date:  1989-09       Impact factor: 8.317

2.  In vitro activation of T lymphocytes from human immunodeficiency virus (HIV)-seropositive blood donors. I. Soluble interleukin 2 receptor (IL2R) production parallels cellular IL2R expression and DNA synthesis.

Authors:  H E Prince; S H Kleinman; V C Maino; A L Jackson
Journal:  J Clin Immunol       Date:  1988-03       Impact factor: 8.317

3.  Antigen-antibody reaction in solution in capture competition immunoassay for human immunodeficiency virus antibodies.

Authors:  C M Nielsen; B Kvinesdal; B F Vestergaard
Journal:  J Clin Microbiol       Date:  1989-07       Impact factor: 5.948

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.